MercachemSyncom, Bionetix, and ProQinase ink AML contractBionetix, ProQinase, and MercachemSyncom have announced that they will jointly develop a new AML drug, from target identification to clinical testing more ➔
iOnctura SA bags €15m in Series A roundMerck KGaA’s 2017 Swiss cancer spin-out iOnctura SA has raised €15m to bring its PI3K? inhibitor and autotaxin inhibitor to the clinic. more ➔
Agriculture ministers commit to global trade rulesMinisters from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based … more ➔
HepaRegeniX: €11m for liver disease treatmentHepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic. more ➔
Nestlé heavily invests in sustainable packaging Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives. more ➔
BioNTech acquires Neon at cheapest for $67mmRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US. more ➔
New stromal target overcomes cancer resistanceBritish researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models. more ➔
Astellas and Adaptimmune team up in CAR-T developmentAdaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells. more ➔
Illumina embraces RocheTwelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. more ➔
Incyte licenses Morphosys’ tafasitamab in US$2bn dealIncyte Corp. has signed a global license agreement for commercialisation of Morphosys AG’s anti-CD-19 programme tafasitamab. more ➔
